Thomas Martin, Md

This early-phase trial tests a personalized cell therapy (CAR T) that targets a protein called BCMA on myeloma cells. It is for people whose multiple myeloma has returned or not responded to at least three prior treatments. The main goal is to check safety and find the right dose…